Ovarian Cancer
-
Johnson & Johnson Ordered To Pay More Than $110 Million In Baby Powder, Shower To Shower Powder Cancer Case
-
Contraceptive Pill May Protect Against Cancer For Up To 30 Years
-
FDA Fast-Tracks Approval For Advanced Ovarian Cancer Drug Rucaparib
-
USPSTF Releases Recommendations On Primary Care Interventions, Highlights Role Doctors Play In Proper Breastfeeding
-
Tesaro, ENGOT Announce Successful Phase 3 Clinical Trial Results For Ovarian Cancer Drug Niraparib
-
More Cancer-Related Talcum Powder Lawsuits Filed Against Johnson & Johnson
-
FDA Warns Against Ovarian Cancer Screening Tests: What Factors Determine Women’s Risk Levels For The Disease?
-
FDA Warns Women Against Results Of Ovarian Cancer Screening Tests
-
Existing Leukemia Drug May Help Fight Specific Ovarian Cancer
-
This Is Why Ovarian Cancer Becomes Resistant To Chemotherapy
-
Jury Orders Johnson & Johnson To Pay $55 Million Over Talc-Based Powder Linked To Ovarian Cancer
-
Women Who Use Genital Talc At Increased Risk Of Ovarian Cancer: Study
Most Popular
